Keros Therapeutics, Inc.: other noncurrent assets

What this measure means

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

Exact concept: us-gaap:OtherAssetsNoncurrent. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.

Coverage of this history

Selected reporting periods run from 2020-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.

Selected filing history

Related financial histories

• Keros Therapeutics, Inc.: total assets
• Keros Therapeutics, Inc.: total liabilities
• Keros Therapeutics, Inc.: stockholders equity
• Keros Therapeutics, Inc.: cash and cash equivalents
• Keros Therapeutics, Inc.: net income or loss
• Keros Therapeutics, Inc.: operating cash flow
• Keros Therapeutics, Inc.: capital expenditure payments
• Keros Therapeutics, Inc.: contract revenue excluding tax
• Keros Therapeutics, Inc.: financing cash flow
• Keros Therapeutics, Inc.: investing cash flow
• Keros Therapeutics, Inc.: retained earnings or deficit
• Keros Therapeutics, Inc.: basic weighted-average shares
• Keros Therapeutics, Inc.: diluted weighted-average shares
• Keros Therapeutics, Inc.: basic earnings per share
• Keros Therapeutics, Inc.: diluted earnings per share
• Keros Therapeutics, Inc.: income tax expense or benefit
• Keros Therapeutics, Inc.: net property, plant and equipment
• Keros Therapeutics, Inc.: share-based compensation expense
• Keros Therapeutics, Inc.: operating income or loss
• Keros Therapeutics, Inc.: current assets
• Keros Therapeutics, Inc.: current liabilities
• Keros Therapeutics, Inc.: current accounts payable
• Keros Therapeutics, Inc.: net current accounts receivable
• Keros Therapeutics, Inc.: operating expenses
• Keros Therapeutics, Inc.: research and development expense
• Keros Therapeutics, Inc.: common shares outstanding
• Keros Therapeutics, Inc.: cash including restricted cash
• Keros Therapeutics, Inc.: additional paid-in capital
• Keros Therapeutics, Inc.: operating lease right-of-use asset
• Keros Therapeutics, Inc.: operating lease liability
• Keros Therapeutics, Inc.: gross property, plant and equipment
• Keros Therapeutics, Inc.: accumulated depreciation on property, plant and equipment
• Keros Therapeutics, Inc.: other noncurrent liabilities
• Keros Therapeutics, Inc.: accrued current liabilities
• Keros Therapeutics, Inc.: prepaid expenses and other current assets
• Keros Therapeutics, Inc.: net deferred tax assets
• Keros Therapeutics, Inc.: pre-tax income or loss from continuing operations
• Keros Therapeutics, Inc.: net income available to common stockholders
• Keros Therapeutics, Inc.: general and administrative expense
• Keros Therapeutics, Inc.: depreciation expense
• Keros Therapeutics, Inc.: other nonoperating income or expense
• Keros Therapeutics, Inc.: nonoperating income or expense
• Keros Therapeutics, Inc.: current income tax expense or benefit
• Keros Therapeutics, Inc.: income taxes paid, net
• Keros Therapeutics, Inc.: operating lease payments
• Keros Therapeutics, Inc.: change in accounts receivable
• Keros Therapeutics, Inc.: change in accounts payable

Inspect the source

Entity

Keros Therapeutics, Inc. / CIK 0001664710

Captured

2026-09-21T17:22:31.454Z

SEC response SHA-256

47240cffe62384e0ef9381e3b6b5a32a684071602d0ea9728d8fcaa516b8dfae

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

• Get an API key and run your first validation
• Connect the MCP server to your coding assistant
• Inspect the ALPHAC engine on GitHub
• Read the MCP server source and integration examples

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001664710.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))